Evidence-based and unlicensed indications for proton pump inhibitors and patients' preferences for discontinuation: A pilot study in a sample of Italian community pharmacies

Journal of Clinical Pharmacy and Therapeutics

Volumn 41, Issue 2, 2016, Pages 220-223

  Pasina, L ^a   Urru, S A M ^b   Mandelli, S ^a   Giua, C ^c   Minghetti, P ^d  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b CENTER FOR ADVANCED STUDIES   (Italy)

^c UNIVERSITY OF TRIESTE   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

Author keywords

community pharmacies; medication appropriateness; pharmacoepidemiology

Indexed keywords

HISTAMINE H2 RECEPTOR ANTAGONIST; PROTON PUMP INHIBITOR;

ADULT; AGED; ARTICLE; COMMUNITY CARE; DRUG INFORMATION; DRUG USE; EVIDENCE BASED MEDICINE; FEMALE; GASTRIC HYPERACIDITY; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL TOXICITY; GENERAL PRACTITIONER; HELICOBACTER INFECTION; HUMAN; INAPPROPRIATE PRESCRIBING; ITALIAN (CITIZEN); MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PATIENT EDUCATION; PATIENT PREFERENCE; PHARMACOEPIDEMIOLOGY; PHARMACY; PILOT STUDY; STOMACH PROTECTION; STOMACH ULCER; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; CROSS-SECTIONAL STUDY; DRUG UTILIZATION; ITALY; MIDDLE AGED; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CROSS-SECTIONAL STUDIES; DRUG UTILIZATION; FEMALE; HUMANS; ITALY; MALE; MIDDLE AGED; PATIENT PREFERENCE; PHARMACIES; PILOT PROJECTS; PROTON PUMP INHIBITORS; YOUNG ADULT;

EID: 84959518346     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/jcpt.12371     Document Type: Article

References (26)

1. Forgacs I, Loganayagam A,. Overprescribing proton pump inhibitors. BMJ, 2008; 336: 2-3.
2. Johnson DA, Oldfield EC,. Reported side effects and complications of long-term proton pump inhibitor use: dissecting the evidence. Clin Gastroenterol Hepatol, 2013; 11: 458-464.
3. Targownik LE, Lix LM, Metge CJ, Prior HJ, Leung S, Leslie WD,. Use of proton pump inhibitors and risk of osteoporosis related fractures. CMAJ, 2008; 179: 319-326.
4. Yang YX, Metz DC,. Safety of proton pump inhibitor exposure. Gastroenterology, 2010; 139: 1115-1127.
5. Cundy T, Mackay J,. Proton pump inhibitors and severe hypomagnesaemia. Curr Opin Gastroenterol, 2011; 27: 180-185.
6. Park CH, Kim EH, Roh YH, Kim HY, Lee SK,. The association between the use of proton pump inhibitors and the risk of hypomagnesemia: a systematic review and meta-analysis. PLoS One, 2014; 9: e112558. doi: 10.1371/journal.pone.0112558.
7. Pasina L, Zanotta D, Puricelli S, Djignefa DC, Bonoldi G,. Proton pump inhibitors and risk of hypomagnesemia. Eur J Intern Med, 2015; 26: e25-e26.
8. Rosa RG, Barros AJ, de Lima AR, et al,. Mood disorder as a manifestation of primary hypoparathyroidism: a case report. J Med Case Rep, 2014; 8: 326.
9. Deroux A, Khouri C, Chabre O, Bouillet L, Casez O,. Severe acute neurological symptoms related to proton pump inhibitors induced hypomagnesemia responsible for profound hypoparathyroidism with hypocalcemia. Clin Res Hepatol Gastroenterol, 2014; 38: e103-e105.
10. Maggio M, Corsonello A, Ceda GP, et al,. Proton pump inhibitors and risk of 1-year mortality and rehospitalization in older patients discharged from acute care hospitals. JAMA Intern Med, 2013; 173: 518-523.
11. Naunton M, Peterson GM, Bleasel MD,. Overuse of proton pump inhibitors. J Clin Pharm Ther, 2000; 25: 333-340.
12. Pasina L, Nobili A, Tettamanti M, et al,. Prevalence and appropriateness of drug prescriptions for peptic ulcer and gastro-esophageal reflux disease in a cohort of hospitalized elderly. Eur J Intern Med, 2011; 22: 205-210.
13. Caro JJ, Salas M, Ward A,. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton pump inhibitors lansoprazole, rabeprazole and pantoprazole compared with omeprazole, ranitidine and placebo: evidence from randomize clinical trials. Clin Ther, 2001; 23: 998-1017.
14. Wu CY, Chan FK, Wu MS, Kuo KN, Wang CB, Tsao CR, Lin JT,. Histamine2-receptor antagonists are an alternative to proton pump inhibitor in patients receiving clopidogrel. Gastroenterology, 2010; 139: 1165-1171.
15. Qvigstad G, Waldum H,. Rebound hypersecretion after inhibition of gastric acid secretion. Basic Clin Pharmacol Toxicol, 2004; 94: 202-208.
16. Ostini R, Jackson C, Hegney D, et al,. How is medication prescribing ceased? A systematic review Med Care, 2011; 49: 24-36.
17. Hoffmann F, Glaeske G, Schmiemann G,. Underuse of proton-pump inhibitors in older patients newly starting NSAID treatment. Int J Clin Pract, 2015; 69: 791-795.
18. Marcum ZA, Hanlon JT, Strotmeyer ES, et al,.; Health, Aging Body Composition Study. Gastroprotective agent underuse in high-risk older daily nonsteroidal anti-inflammatory drug users over time. J Am Geriatr Soc, 2014; 62: 1923-1927.
19. Urru SA, Pasina L, Minghetti P, et al,. Role of community pharmacists in the detection of potentially inappropriate benzodiazepines prescriptions for insomnia. Int J Clin Pharm, 2015; 37: 1004-1008.
20. Pasina L, Urru SAM, Giua C, Minghetti P,. Role of community pharmacies for the detection of potentially inappropriate xanthine oxidase inhibitor prescriptions. Drugs Real World Outcomes, 2015; 2: 81-86.
21. Scott IA, Hilmer SN, Reeve E, et al,. Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Intern Med, 2015; 175: 827-834.
22. A practical guide to stopping medicine in older people. Best Pract J, 2010; 27: 11-22. Available at: www.bpac.org.nz/magazine/2010/april/stopGuide.asp (accessed 23 February 2016).
23. Curtain C, Peterson GM, Tenni P, Bindoff IK, Williams M,. Outcomes of a decision support prompt in community pharmacy-dispensing software to promote step-down of proton pump inhibitor therapy. Br J Clin Pharmacol, 2011; 71: 780-784.
24. Freedberg DE, Salmasian H, Abrams JA, Green RA,. Orders for intravenous proton pump inhibitors after implementation of an electronic alert. JAMA Intern Med, 2015; 175: 452-454.
25. Heinze G, Jandeck LM, Hronsky M, et al,. Prevalence and determinants of unintended double medication of antihypertensive, lipid-lowering, and hypoglycemic drugs in Austria: a nationwide cohort study. Pharmacoepidemiol Drug Saf, 2016; 25: 90-99.
26. Tannenbaum C, Martin P, Tamblyn R, et al,. Reduction of inappropriate benzodiazepine prescriptions among older adults through direct patient education: the EMPOWER cluster randomized trial. JAMA Intern Med, 2014; 174: 890-898.